NEW YORK -- Pharmaceuticals were strong on Friday, and upside options were really flowing in Bristol-Myers Squibb
OptionMonster's tracking systems detected bullish activity at two strikes in particular. Traders started with the shorter-term Weekly 54 calls expiring on Dec. 6, snapping up more than 5,000 contracts in volume well above previous open interest of 1,316. Premiums rose from 22 cents to 41 cents, with most of the large blocks pricing for 24 cents to 34 cents. .
These long calls lock in the price where a stock can be purchased, letting investors profit from a rally while risking only small amounts of capital. Their cheap cost also offers the potential for significant leverage if the drug maker pushes higher.
About an hour later, buyers turned to the March 52.50 calls, mostly paying $2.92. Some 5,400 changed hands against open interest of 1,047 contracts.
Bristol-Myers ended the session up 2.02% to $53.41. The company received a key upgrade from Morgan Stanley on Oct. 28 based on the promise of its cancer treatments. Shares have been consolidating at their highest levels in more than a decade since then.
Total option volume in the name was four times greater than average in the session. Overall calls outnumbered puts by almost 5 to 1.
Russell has no positions in BMY.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts